Supplementary Table:
Summary of main adverse events in patients evaluable for toxicity (n=76), who received at least first cycle of regorafenib treatment.
The table shows also frequency, reason and timing of dose reductions.

Toxicities	**G1-G2** *n* (%)	**G3-G4** *n* (%)
Hypertension	11 (14%)	10 (13%)
Skin rash	10 (13%)	7 (9%)
Hand-foot syndrome	20 (26%)	15 (20%)
Mucositis	16 (21%)	4 (5%)
Diarrhea	8 (10%)	3 (4%)
Bilirubin increase	16 (21%)	1 (1%)
AST/ALT increase	13 (17%)	1 (1%)
Thrombocytopenia	8 (10%)	0
Anemia	7 (9%)	0
Other toxicities	37 (49%)	14 (18%)
Dose reduction	41/74 (55%)	
Dose reduction -1 dose level	29/41 (70%)	
Dose reduction -2 dose level	12/41 (30%)	
Reason for dose reduction		
Hypertension	1/41 (2%)	
Skin rash / HFS	20/41 (49%)	
Mucositis	2/41 (5%)	
Diarrhea	2/41 (5%)	
Other	16/41 (39%)	
Dose reduction occurs		
During first cycle	18/41 (44%)	
At second cycle	12/41 (29%)	
At third cycle	5/41 (12%)	
After fourth cycle	6/41 (15%)	
Stop for toxicities	10/76 (13%)	